COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
25/03/2025
Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and [...]
SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
24/03/2025
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
24/03/2025
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, [...]
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
24/03/2025
BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be [...]
OrthoPediatrics Corp. Named One the 2025 Best Places to Work in Indiana
24/03/2025
WARSAW, Ind., March 24, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) , a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Option Care Health to Announce First Quarter 2025 Financial Results and Host Conference Call
24/03/2025
BANNOCKBURN, Ill., March 24, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today [...]
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
24/03/2025
First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for [...]
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
24/03/2025
– Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for [...]
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
24/03/2025
Initial data for AlloNK ® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical [...]
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
24/03/2025
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted [...]
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
24/03/2025
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $ [...]
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
24/03/2025
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40 th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to [...]
Acutus Medical Reports Full Year 2024 Financial Results
24/03/2025
CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing [...]
Abinopharm, Inc. warmly congratulates partner company EGT Synbio on receiving no objection letter from the FDA for their GRAS notification of Dr.Ergo®Ergothioneine
24/03/2025
SHELTON, Conn., March 24, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative nutritional and biopharmaceutical company, is pleased to announce that their partner company, EGT Synbio, has received no objection [...]
Whispeara Reviews (Complaints & Side Effects): Buyers Reveal Unexpected Truths Behind Its Real Effectiveness
24/03/2025
SEATTLE, March 24, 2025 (GLOBE NEWSWIRE) -- Hearing issues affect millions worldwide, turning daily interactions into struggles and stealing away the joy of life's simplest moments. Supplements promising miraculous [...]
Tonic Greens Reviews (Complaints & Side Effects): Buyers Reveal Unexpected Truths Behind Its Real Effectiveness
24/03/2025
Tonic Greens sparks debate as real users share mixed reviews, uncovering both impressive wellness claims and unexpected side effects in 2025. Seatle, March 24, 2025 (GLOBE NEWSWIRE) -- Tonic Greens With immune-boosting [...]
ProDentim Reviews (Complaints & Side Effects): Buyers Reveal Truths About Their Dental Improvements
24/03/2025
SEATTLE, March 24, 2025 (GLOBE NEWSWIRE) -- In the fast-growing realm of oral health solutions, ProDentim has rapidly become one of the most talked-about probiotic supplements. With claims of revolutionary results [...]
Provadent: The Science-Backed Supplement for Stronger Teeth & Gums
24/03/2025
TALLMADGE, Ohio, March 24, 2025 (GLOBE NEWSWIRE) -- Lately, more people are grappling with dental health problems. Whether it's cavities, gum disease, or just a dull ache that won’t go away, these issues are hard to [...]
Spineway : Consolidated 2024 annual results - Operating income close to breakeven
24/03/2025
Press release Ecully, March 24, 2025 – 6 p.m. SPINEWAY Consolidated 2024 annual results Annual revenue of €12 million (+14%) Operating income close to breakeven Reduction in net loss In thousands of euros Consolidated [...]

Pages